Abstract Purpose: This phase I infusion rate escalation trial was undertaken to evaluate the maximum applicable infusion rate for rituximab without steroid premedication in patients having received one previous rituximab infusion. Experimental Design: Cohorts of at least three patients were assigned to rituximab with or without concomitant chemotherapy. The initial infusion rate was 200 mg/h in the first cohort, and was increased by 100 mg/h in each subsequent cohort to a maximum of 700 mg/h. In each patient the infusion rate was increased by 100 mg/h every 30 minutes to the total dose (375 mg/m 2 ). In the first six cohorts (21 patients), two well-tolerated rituximab administrations were required; in the 7th cohort (11 patients) one previously well-tolerated rituximab infusion was required. Patients did not receive steroid premedication and were monitored with electrocardiograms (ECG), echocardiograms, Holter ECGs, troponin, and brain natriuretic peptide (BNP). Results: Thirty-two patients were included and 128 cycles were done, 85 at a rate of 700 mg/h. Patients tolerated infusion rates without major side effects. There were no new clinically relevant ECG alterations. Troponin (< 0.1ng/L) and mean cardiac ejection fraction (65%) remained in the reference range; BNP baseline level increased significantly 24 hours after rituximab administration (from 30.4 to 64.1ng/L; P < 0.0001).
Rituximab is a monoclonal antibody against the lymphocyte surface antigen CD20. First introduced in 1995 for the treatment of non -Hodgkin's B-lymphoma, rituximab has today a broad spectrum of indications, including treatment of rheumatoid arthritis, thrombotic thrombocytopenic purpura, and systemic lupus erythematosis, among many others (1 -6) . Treatment with rituximab is generally well tolerated and can be combined with chemotherapy, improving response rate, response duration, and in some cases overall survival of patients with B-cell lymphomas (1) . Infusion-related reactions can occur in approximately one fourth of patients during the first administration, probably due to a release of cytokines into the blood as a consequence of the rapid destruction of circulating B cells (7) . This is why it is recommended to choose a low initial infusion rate. The incidence and the severity of infusion-related side effects consistently decrease in the successive administrations; indeed after the second rituximab infusion almost no B cells are left in the blood for at least 2 to 3 months. The reconstitution begins usually after 6 months and is completed after a median of 12 months (8, 9) . We hypothesized that no infusion-related reaction should occur from the second infusion, and that a faster application of rituximab could be considered safe. Although the duration of the infusion is usually 4 to 5 hours for the first administration, the present study was undertaken to evaluate if from the second infusion rituximab could be administered over 1 hour.
Patients and Methods
Patient eligibility. Patients with any type of B-cell lymphoma were eligible. In the first part of the study (21 patients) two previous welltolerated rituximab administrations (the last one given no longer then 3 mo before) were required, whereas in the second part (11 patients) one previous rituximab infusion in the previous 3 mo was accepted. The first rituximab administration(s) should be given according to the manufacturer's guidelines (10) . Rituximab could be given with chemotherapy, provided the latter (including steroids) was administered after rituximab infusion. A left ventricular ejection fraction of z50% (assessed by echocardiography in the month before inclusion) was required. No severe reaction to prior rituximab infusions could have occurred.
Exclusion criteria were concomitant participation to other clinical trials, previous history of cardiovascular disease including congestive heart failure, unstable angina, significant arrhythmia, or a myocardial infarction in the year before inclusion in the study.
The trial was approved by the local ethics committee and all patients had to give written informed consent according to institutional guidelines.
Study design. Cohorts of at least three patients were assigned to receive rituximab (Fchemotherapy) at a given initial infusion rate of 200 mg/h, which was then increased by 100 mg/h in each subsequent cohort to a maximal predefined initial infusion rate of 700 mg/h. At each administration, the infusion rate was increased by 100 mg/h every 30 min to the prescribed total dose (375 mg/m 2 ; Table 1 ). All patients received standard antihistamine (clemastine-Tavegyl) and paracetamol premedication, according to the manufacturer's recommendations, without steroid premedication. If no serious adverse event occurred during the infusion in three patients, the next cohort was opened. In case of a serious adverse event, three additional patients were to be included in the same cohort. If two patients experienced serious adverse events, the previous infusion rate would be considered the maximum tolerated infusion rate.
For patients receiving chemoimmunotherapy, rituximab always preceded chemotherapy and was administered on the same day.
Toxicity assessment. Toxicity grading was evaluated by the National Cancer Institute's Common Toxicity Criteria (v3.0). Clinical exam was done before each cycle; vital signs (temperature, blood pressure, heart rate) and symptoms were assessed every 15 min during infusion. A laboratory exam with complete blood cell count and chemistry were repeated before each cycle. Circulating B cells (CD19) were evaluated by immunophenotyping before the first rapid infusion and before each subsequent infusion.
Electrocardiogram (ECG) monitoring (before, during, and 30 min from the end of infusion) was done in the six initial cohorts; troponin I, brain natriuretic peptide (BNP) measurements, echocardiogram (with left ventricular ejection fraction, and systolic and diastolic function), and Holter ECG monitoring at baseline and 24 h after administration of rituximab, were additionally done in the seventh cohort.
Statistical analysis. Mean, median, and SD were used to characterize results. Paired sample t test was used to assess significance between parameters (SPSS for Windows 15.0, SPSS Inc.). A P < 0.05 was considered significant.
Results
Thirty-two patients with B-cell lymphoma with a median age of 57.5 years (range 24-77 years) entered the study. Table 2 reports patient characteristics. The first six cohorts (21 patients) included subjects who had two rituximab administrations before entering the trial, whereas in the 7th cohort (11 patients) all patients had only one. Overall 128 rituximab cycles were administered. Three were given at a starting infusion rate of 200 mg/h, 7 at 300 mg/h, 11 at 400 mg/h, 11 at 500 mg/h, 11 at 600 mg/h, and 85 at 700 mg/h. No severe side effects were observed (Table 3) .
Data on circulating B cells, blood pressure, temperature, troponin, and BNP were available for 83%, 80%, 82%, 94%, and 92% of infusions, respectively. Final echocardiography was done in 72% of patients.
Mean systolic and diastolic blood pressure or heart rate did not change significantly during the infusions, with the exception of one patient who developed grade 1 hypotension. Temperature never increased above 37.1jC. Grade 1 headache and dyspnea were seen in four and one patient, respectively. There were no new clinically relevant ECG alterations, but one patient repeatedly showed convex ST-segment elevations over V2 and V3 leads and T-flattening under maximal rituximab infusion rate. No concomitant risk factors were present. In this patient, premedication (clemastine, paracetamol) alone, or an infusion of saline solution without rituximab did not cause the described alterations. BNP and troponin I levels remained always in the reference range. Although the patient was asymptomatic, the infusion rate was reduced in the following infusions for safety reasons. For all patients, troponin I levels did not change significantly, remaining within a reference range (<0.1 ng/L) before and after the rapid infusion. 1  50  100  200  300  400  500  600  700  Cohort 2  50  100  300  400  500  600  700  700  Cohort 3  50  100  400  500  600  700  700  700  Cohort 4  50  100  500  600  700  700  700  700  Cohort 5  50  100  600  700  700  700  700  700  Cohort 6  50  100  700  700  700  700  700  700  Cohort 7  50  700  700  700  700  700  700  700 Translational Relevance
We consider our work as relevant to daily practice because it confirms the safety of administering rituximab at an infusion rate of 700 mg/h, including from a cardiologic point of view. A shorter infusion leads to lower costs and shorter time of therapy for patients. Even if already used at higher infusion rates worldwide, rituximab administered over 1 hour or 90 minutes, without steroid premedication, was never tested in a phase I rate escalation setting. Safety concerns about the cardiac effects of rituximab had been raised, most notably during the first application; thus, having monitored patients during the highest infusion rate with Holter electrocardiogram and blood parameters (troponin, brain natriuretic peptide) is a strong point of our study. unchanged 1 month after the end of treatment. Holter ECG monitoring after completion of the infusion showed no pathologic changes compared with baseline (n = 11).
Circulating B cells were low before the first rapid infusion in all patients, including those having received only one previous rituximab infusion. No significant changes were reported in the follow up, and B-cell values remained in very low range (Fig. 1) .
Discussion
We have shown that the administration of rituximab with a maximal dose of 700 mg over 60 minutes without steroid premedication is feasible and safe, provided one well-tolerated rituximab dose had been given in the previous 3 months. The very low number of circulating B cells from the second administration on, as shown by blood immunophenotyping, can explain the lack of infusion reactions.
Because of previous reports of a possible cardiac toxicity in the 24 hours after rituximab administration (myocardial infarction, arrhythmia, ventricular fibrillation, and cardiogenic shock) an extensive cardiologic evaluation was done concomitantly to evaluate whether the increased infusion rate induced cardiotoxicity (9) . Only one patient showed totally asymptomatic ECG alterations (repolarization disorder) of still uncertain origin. This alteration was correlated to rituximab infusionalthough a coronary heart disease was not formally ruled out-and after a reduction of the infusion rate, no further ECG alterations were reported.
In all cases, normal troponin values along with unchanged echocardiograms and Holter ECGs confirmed the lack of cardiotoxic effect of a fast infusion rate. The observed increase in BNP values 24 hours after infusion is to be considered nonspecific, because values remained in all but one case within the reference range and always returned to baseline values. The explanation for this BNP variation could be the slight volume overload caused by the fast infusion (11) .
Overall, 85 infusions could be safely administered over 1 hour; in only 11 patients, however, was this rate applied at second rituximab infusion, and additional data are needed before this schedule can be proposed for standard daily practice.
Sehn et al. first reported a prospective observation of 150 patients receiving a total of 473 administrations of rituximab in 90 minutes. The safety and feasibility of this schedule was confirmed by a retrospective analysis of a further 1,200 patients treated in British Columbia (12) . In this study, part of the rituximab administrations was given as maintenance; in 52 of these cases, treatment was given without steroid premedication without any grade 3-4 toxicities being observed.
Similar conclusions were reached in two further Spanish studies. Salar et al. treated 70 patients with 319 administrations of rituximab over 90 minutes without steroid premedication in (13) . No grade 3 or 4 toxicities were seen. Provencio et al. described a total of 233 administrations over 60 minutes, with only minor toxicities reported (14) . The study was conducted prospectively and included 40 patients, who received steroids as premedication.
Overall, in these studies rituximab was safely administered in 90 minutes with/without steroids or in 60 minutes with steroids (12 -16) . Our study is the only one done following a formal phase I-II design to define the maximum infusion rate and showing that a 700 mg/h infusion rate without steroid premedication is safe. This schedule is advantageous for patients (with a shorter stay in the clinic), for health providers (because it reduces the use of hospital/clinic resources), and for health insurances (in countries where costs are dependent on treatment time). This is particularly true now because the advantages of Fig. 1 . B-cell number (CD19) for all patients (A) in cohorts 1to 6 (B) and cohort 7 (C) versus cycle number.
